title: The pharmacoeconomics of high-cost biotechnology products.
abstract: Biotechnology products have created therapy options in areas that have been historically limited. These improvements in patient care have resulted in a reappraisal of the emphasis placed on product acquisition costs and a movement toward evaluating the impact of the product on the entire health care system. Strategic planning for biotechnology products allows pharmacists to partner with the medical staff and financial/administrative representatives of the institution to measure clinical outcomes, estimate cost and revenue impact, document utilization, and promote cost-effective use of these new therapies to generate the maximum benefit for dollars expended.
authors: Univ. of Texas, M.D. Anderson Cancer Ctr., Houston TX 77030, USA.
authors: W J
authors: WJ
authors: Dana
authors: K
authors: K
authors: Farthing
mesh_terms: D001709:Biotechnology / Q000191:economics*; D002986:Clinical Trials as Topic / Q000191:economics; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs / Q000706:statistics & numerical data; D004358:Drug Therapy / Q000191:economics*; D005572:Formularies, Hospital as Topic; D006801:Humans; D010934:Planning Techniques; D013678:Technology, Pharmaceutical / Q000191:economics*; D016896:Treatment Outcome; D014481:United States